臨床薬理の進歩　No.43

64/238

＊0ⅠⅡⅣ＊＊＊＊＊Total No.Female58 (16%)Male305 (84%)65.2 ± 12.4170 (47%)193 (53%)22.7 ± 3.4175 (49%)185 (51%)56.4 ± 30.7165 (45%)198 (55%)TypeⅠ52 (14%)TypeⅡ 259 (72%)TypeⅢ52 (14%)Absent257 (71%)Present106 (29%)80 (22%)pT153 (15%)pT2132 (36%)pT398 (27%)pT4134 (37%)pN076 (21%)pN161 (17%)pN292 (25%)pN335.3 ± 17.94.5 ± 6.8M0307 (85%)M156 (15%)94 (26%)49 (14%)Ⅲ 164 (45%)56 (15%)p (across 3 MSI status)MSS(N=311)0.3947 (15%)264 (85%)64.8 ± 12.30.0070.12140 (45%)171 (55%)22.6 ± 3.50.80155 (50%)0.35154 (50%)56.3 ± 30.20.44141 (45%)0.56170 (55%)0.1548 (15%)222 (72%)41 (13%)0.77218 (70%)93 (30%)0.9467 (22%)44 (14%)113 (36%)87 (28%)0.018105 (34%)66 (21%)52 (17%)88 (28%)35.3 ± 18.00.925.0 ± 7.20.00120.10258 (83%)53 (17%)0.04477 (25%)36 (12%)145 (46%)53 (17%)Clinicopathological featuresBefore Dec. 2009Jan. 2010 to Jan. 2015 ＜22.5 (median)≧22.5 (median)＜50 (median)≧50 (median)MSI statusMSI-H(N=28)MSI-L(N=24)7 (25%)4 (17%)21 (75%)20 (83%)71.7 ± 11.362.7 ± 11.814 (50%)16 (67%)14 (50%)8 (33%)23.1 ± 3.222.6 ± 3.511 (39%)9 (39%)17 (61%)14 (61%)62.9 ± 37.950.0 ± 28.011 (39%)13 (54%)17 (61%)11 (46%)4 (17%)22 (79%)15 (62%)6 (21%)5 (21%)21 (75%)18 (75%)7 (25%)6 (25%)7 (25%)6 (25%)4 (14%)5 (21%)11 (40%)8 (33%)6 (21%)5 (21%)18 (64%)11 (46%)5 (18%)5 (21%)4 (14%)5 (21%)1 (4%)3 (13%)35.3 ± 19.535.0 ± 14.81.5 ± 3.42.3 ± 3.227 (96%)22 (92%)1 (4%)2 (8%)10 (35%)7 (29%)8 (29%)5 (21%)9 (32%)10 (42%)1 (4%)2 (8%)表1　非EBV関連腫瘍におけるMSIステータス別の臨床病理学的・分子生物学的特徴（N=363）SexAge at surgery (y, mean ± SD)Year of surgeryBody mass index (kg/m2, mean ± SD) Tumor diameter (mm, mean ± SD) Siewert classificationBarrett's esophaguspT StagepN StageNo. of nodes harvested (mean ± SD)No. of metastatic nodes (mean ± SD)M stagepStageMSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSS, microsatellite stable.50